A Phase 4 interventional study of Educational Material and Standard of care in Atherosclerotic Cardiovascular Disease, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in United Arab Emirates. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Atherosclerosis by Novartis — 4 open to participants now, 10 under way, 3 of them phase 3. Atherosclerosis · Novartis.
Among the 27 studies in Atherosclerosis by Novartis, this one is the 13th largest by planned enrollment of the 18 interventional ones that give a count, is one of 7 that started in 2025, is one of 3 in phase 4, and was the 25th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →4 of the 27 studies in Atherosclerosis by Novartis are open now, in 5 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Switzerland
Ages 18–99
Novartis Pharmaceuticals · Sites in Russia
Ages 18–99
Novartis Pharmaceuticals · Sites in Argentina, Brazil
Ages 18–100
By country, each count listing its studies:
Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 10 · Phase 4 3
First in 2006; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 326 is above the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 426 across the 18 interventional studies, 2,125 across the 8 observational. Of the 16 that completed or were terminated, 10 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
6 of the studies in Atherosclerosis by Novartis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06501443Novartis PharmaceuticalsLATAM LOWERS LDL-C | 2026-11-27 |
| NCT07235046Novartis PharmaceuticalsA Study of DII235 in Adults With Elevated Lipoprotein(a) | 2027-04-26 |
| NCT06958315Novartis PharmaceuticalsInclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study | 2027-05-01 |
| NCT07034690Novartis PharmaceuticalsStudy to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia | 2027-05-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 27 studies in Atherosclerosis by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is an open label, randomized, prospective, type I hybrid effectiveness- implementation, pragmatic clinical trial to evaluate the impact of a targeted lipid optimization program on LDL-C control in participants with dyslipidemia who are at high risk or very high risk of cardiovascular events.
The treatment of interest is a lipid optimization program in the form of a health education intervention delivered via clinic visits (every 4 months) and virtual sessions (between each clinic visit).
No active drug treatment will be provided. The intervention in this study will involve the implementation of a lipid optimization, education program for patients at high risk and very high risk of cardiovascular events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Lipid levels:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive Health Education Intervention alongside standard of care
Other: Educational Material · Other: Standard of care
Participants receive Standard of care
Other: Standard of care
Health Education Intervention delivered via clinic visits (every 4 months) and virtual sessions (between each clinic visit)
Standard of care
Percentage of participants achieving target LDL-C goals based on CV risk
Percentage of participants achieving target Low-Density Lipoprotein Cholesterol (LDL-C) goals based on Cardiovascular (CV) risk stratified by group: * Very high risk: \<55 mg/dl * High risk: \<70 mg/dl
Time frame: Baseline, month 12
Percentage of participants achieving or maintaining target LDL-C goals based on CV risk
Percentage of participants achieving or maintaining target Low-Density Lipoprotein Cholesterol (LDL-C) goals based on Cardiovascular (CV) risk stratified by group: * Very high risk: \<55 mg/dl * High risk: \<70 mg/dl
Time frame: Baseline, month 24
Change of LDL-C
Change of Low-Density Lipoprotein Cholesterol (LDL-C) from baseline at 12 months and 24 months in both study groups
Time frame: Baseline, month 12 and month 24
Change in the proportion of participants receiving advanced lipid lowering therapies
Change in the proportion of participants receiving advanced lipid lowering therapies at 12 months and 24 months from baseline, for each group
Time frame: Month 12 and Month 24
Proportion of participants from the intervention group who complete all visits
Proportion of participants from the intervention group who complete all: * In clinic visits * Virtual sessions
Time frame: 24 months
Proportion of participants from the intervention group who discontinue the education program
Proportion of participants from the intervention group who discontinue the education program before the 12 month study visit
Time frame: 12 months
Proportion of days covered
Proportion of days covered (for statins and non-statin lipid therapies)
Time frame: Baseline, month 12 and month 24
Number of hospitalizations
Number of hospitalizations during the 12 month active intervention period and the 12 month follow up period
Time frame: 24 months
Number of outpatient visits
Number of outpatient visits during the 12 month active intervention period and the 12 month follow up period
Time frame: 24 months
Number of ER visits
Number of Emergency Room (ER) visits during the 12 month active intervention period and the 12 month follow up period
Time frame: 24 months
Associated costs
Associated costs during the 12 month active intervention period and the 12 month follow up period
Time frame: 24 months
Number of LDL-C tests performed
Number of Low-Density Lipoprotein Cholesterol (LDL-C) tests performed, analyzed according to: * Site (clinic) * Healthcare Professional (HCP) specialty (Cardiologists, Endocrinologists, internist, etc.) * Baseline characteristics (e.g. age, sex, ethnicity, Cardiovascular risk status)
Time frame: 24 months
Change in knowledge awareness scores:
Awareness regarding lipid management amongst those participants in the intervention group will be measured using a knowledge awareness questionnaire. The same questionnaire will be administered at baseline, 12 months and 24 months, enabling scores to be compared across the study duration. The knowledge awareness questionnaire scale has a minimum score of 0 and maximum score of 17 points. A high score will indicate higher participant awareness.
Time frame: Baseline, month 12 and month 24
Change in WHO BREF quality of life scores
WHO BREF questionnaire assesses QoL across four main domains: physical health, psychological health, social relationships, and environmental health. Participants will respond to each item using a Likert scale (ranging from 1 to 5) indicating their level of agreement or satisfaction. Higher scores typically indicate better QoL.
Time frame: Baseline, month 12 and month 24
Qualitative surveys among focus groups of HCPs and participants to evaluate implementation outcomes
Implementability of the lipid optimization program will be assessed during focus group sessions that explore satisfaction, costs, and acceptance of the program from the perspective of HCPs and participants
Time frame: month 12 and month 24
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for May 2027, 18 months after the start.
Of 55 phase 4 interventional studies under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's planned 18 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.